Neoplasms Clinical Trial
Official title:
Determinants of Physical Activity Level in Pediatric Oncological Patients Treated With Cardiotoxic Therapy - a Study Protocol
Cancer treatment in children is very effective, but unfortunately has side effects - unwanted, bad impact. Some drugs that are given during cancer treatment, in addition to their good effect, can affect the heart badly and can lower the physical activity tolerance, such as climbing stairs, fast walking, running, exercise. Physical activity is very important for the proper growth and development of children and future adults. Heart is an important organ pumping the blood around the body and its good function is one of the key determinants of physical activity level in humans. The goal of this study is to is to find what impacts physical activity level in children treated for cancer with treatment methods that may be toxic to the heart to learn about influence of this treatment on the physical activity level of these children. The main questions this study aims to answer are: - Do children after cancer treatment involving heart toxic treatment methods present lower level of daily physical activity in comparison to the children treated with different methods? - Is the level of physical activity related to the heart toxic treatment, or other such as exercise capacity (measured physical strength on the treadmill or standing bike), quality of life, lifestyle, social and demographic factors, body type as well as the knowledge about positive impact of physical activity, efficacy, and motivation to physical activity? Participants will: - fill in the questionnaire, - perform an exercise test on the treadmill or standing bike (to measure exercise capacity), - perform ALPHA test (physical fitness test) consisting of some simple exercise like jumping, running etc., - be measured and weighted, - be measured by the hand-grip test with the hand dynamometer machine, - wear activity-tracker band for 14 days, - be examined by the ultrasound of the heart (echocardiography). Researchers will compare 144 children treated with heart toxic methods for cancer to 144 children treated for cancer with non-toxic methods. The children will be aged 8-18 years old and will be 1-5 years after treatment for cancer. The researchers believe that finding what influences physical activity level in children after cancer treatment with heart toxic methods may - make the therapy for cancer in children better, with less side effects - by that, can cause increase in the physical activity and ensure better growth and health for these children in the future.
Status | Not yet recruiting |
Enrollment | 290 |
Est. completion date | June 30, 2026 |
Est. primary completion date | June 30, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 8 Years to 18 Years |
Eligibility | Inclusion Criteria: Study group: - age 8-18 years, - diagnosis and completed treatment for cancer >1 year and <5 years ago, - remission of the cancer, - treatment involving use of anthracyclines, kinase inhibitors targeting BRC-ABL, hae-mopoietic stem cell transplantation and radiotherapy (TBI or mediastinum irradiation), - at least 6 weeks from the last signs or symptoms of an infection, - written consent signed by the parents and patients aged =16 years. Control group: - the same as for the experimental group and, - cancer treatment without use of anthracyclines, kinase inhibitors targeting BRC-ABL, haemopoietic stem cell transplantation and radiotherapy (TBI or mediastinum irradiation). Exclusion Criteria: - past history of cancer and its treatment with or without the use of anthracyclines, kinase inhibitors targeting BRC-ABL, haemopoietic stem cell transplantation and radiotherapy (TBI or mediastinum irradiation), - acute infection, - active acute inflammatory disease including: autoimmunological, neurological, pul-monological, endocrinological, cardiovascular, gastrointestinal, - platelet count < 20 G/L, - hemoglobin concentration < 9g /dL, - severe residual changes (protein loss syndrome, peritoneal, pericardial or pleural effu-sion, arrhythmia, metabolic disorders), - previously diagnosed congenital heart defects or other heart diseases (including cardi-omyopathy, heart failure, arrythmia), - relapse of the cancer at the moment of the enrollment to the study, - severe malnutrition <3 SD BMI weight-for-age, - lack of consent, - lack of patient cooperation. Additional exclusion criteria to conduct cardiopulmonary exercise test (CPET): - contraindications to CPET examination including chronic cardiovascular diseases or musculoskeletal system disorders, - excessive malaise (1 year after the treatment for the study group and the control group 1), - intellectual disability, - musculoskeletal system impairment, - chronic concomitant diseases, especially endocrinological, neurological, gastroin-testinal, pulmonological, - lack of cooperation during the CPET. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Medical University of Warsaw |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Physical activity level measured by the accelerometer | Physical activity level measured by the accelerometer and the assessment of the WHO pediatric, age-adjusted physical activity norms achievement | 14 days measurement for 1 individual | |
Secondary | Percentage of participants disqualified from CPET | Percentage of participants disqualified from cardio-pulmonary exercise test (CPET) examination - objective assessment of exercise capacity | Measured at the enrollment | |
Secondary | Exercise capacity measured in CPET | VO2max below 47mL/kg/min for boys and 42 mL/kg/min for girls will be defined as the exercise capacity alterations in cardio-pulmonary exercise test | Measured at the enrollment | |
Secondary | Physical function in the ALPHA test battery | defining of the physical function level as low, moderate or high according to the ALPHA test battery | Measured at the enrollment | |
Secondary | Cardiac function | GLS (Global longitudinal strain) below average for age as well as the normal systolic function will be defined as a LVDd (Left ventricle diastolic diameter) within the normal limit and EF (ejection fraction) 55% or more, as well as the comparison to the control group | Measured at the enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
Completed |
NCT03190811 -
Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors
|
Phase 1/Phase 2 |